Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals Inc (NQ: AVIR )

2.940 +0.010 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atea Pharmaceuticals Inc

< Previous 1 2 Next >
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Combination Offers Opportunity to Improve Standard of Care with Potential for Short Duration, Protease Inhibitor-Free Treatment 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Highlighted for Surprising Price Action
Via Investor Brand Network
Exposures COVID-19
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:AVIR Investor Notice: Investigation over Potential Wrongdoing at Atea Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 04/05/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Atea Pharmaceuticals, Inc. 
Via SBWire
NASDAQ:AVIR Investor Notice: Investigation over Possible Securities Laws Violations by Atea Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 02/02/2022 -- Atea Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.